Only the low dose 2.5 mg × 2 daily resulted in significantly reduced all-cause ... Approximately 4 % of the participants in the thromboprophylaxis trials with dabigatran and enoxaparin for patients ...

A nonstatin lipid-lowering agent (eg, ezetimibe, evolocumab, alirocumab, inclisiran, bempedoic acid) is recommended for patients already on maximally tolerated statin who have a low-density ...

Ready to start planning your care? Call us at 800-525-2225 to make an appointment.

This progress includes the introduction of advanced technologies and local manufacturing of high-quality products, such as the Kingdom's first fully developed biosimilar (enoxaparin) and the region's ...